Literature DB >> 20702619

Neuropeptide Y has a protective role during murine retrovirus-induced neurological disease.

Min Du1, Niranjan B Butchi, Tyson Woods, Timothy W Morgan, Karin E Peterson.   

Abstract

Viral infections in the central nervous system (CNS) can lead to neurological disease either directly by infection of neurons or indirectly through activation of glial cells and production of neurotoxic molecules. Understanding the effects of virus-mediated insults on neuronal responses and neurotrophic support is important in elucidating the underlying mechanisms of viral diseases of the CNS. In the current study, we examined the expression of neurotrophin- and neurotransmitter-related genes during infection of mice with neurovirulent polytropic retrovirus. In this model, virus-induced neuropathogenesis is indirect, as the virus predominantly infects macrophages and microglia and does not productively infect neurons or astrocytes. Virus infection is associated with glial cell activation and the production of proinflammatory cytokines in the CNS. In the current study, we identified increased expression of neuropeptide Y (NPY), a pleiotropic growth factor which can regulate both immune cells and neuronal cells, as a correlate with neurovirulent virus infection. Increased levels of Npy mRNA were consistently associated with neurological disease in multiple strains of mice and were induced only by neurovirulent, not avirulent, virus infection. NPY protein expression was primarily detected in neurons near areas of virus-infected cells. Interestingly, mice deficient in NPY developed neurological disease at a faster rate than wild-type mice, indicating a protective role for NPY. Analysis of NPY-deficient mice indicated that NPY may have multiple mechanisms by which it influences virus-induced neurological disease, including regulating the entry of virus-infected cells into the CNS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20702619      PMCID: PMC2953205          DOI: 10.1128/JVI.01022-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  Neurovirulence of polytropic murine retrovirus is influenced by two separate regions on opposite sides of the envelope protein receptor binding domain.

Authors:  Karin E Peterson; Susan Pourciau; Min Du; Rachel Lacasse; Melissa Pathmajeyan; David Poulsen; Mavis Agbandje-McKenna; Kathy Wehrly; Bruce Chesebro
Journal:  J Virol       Date:  2008-06-25       Impact factor: 5.103

2.  Oligodendrocytes are a major target of the toxicity of spongiogenic murine retroviruses.

Authors:  Amanda C Clase; Derek E Dimcheff; Cynthia Favara; David Dorward; Frank J McAtee; Lindsay E Parrie; David Ron; John L Portis
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

3.  Neuropeptide Y suppresses absence seizures in a genetic rat model primarily through effects on Y receptors.

Authors:  Margaret J Morris; Emma Gannan; Leanne M Stroud; Annette G Beck-Sickinger; Terence J O'Brien
Journal:  Eur J Neurosci       Date:  2007-02       Impact factor: 3.386

4.  Neuroinvasion of fluorescein-positive monocytes in acute simian immunodeficiency virus infection.

Authors:  Candice C Clay; Denise S Rodrigues; Yan S Ho; Beth A Fallert; Kim Janatpour; Todd A Reinhart; Ursula Esser
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

5.  Differential actions of NPY on seizure modulation via Y1 and Y2 receptors: evidence from receptor knockout mice.

Authors:  En-Ju Deborah Lin; Deborah Young; Kristin Baer; Herbert Herzog; Matthew J During
Journal:  Epilepsia       Date:  2006-04       Impact factor: 5.864

6.  The type I interferon system protects mice from Semliki Forest virus by preventing widespread virus dissemination in extraneural tissues, but does not mediate the restricted replication of avirulent virus in central nervous system neurons.

Authors:  Rennos Fragkoudis; Lucy Breakwell; Clive McKimmie; Amanda Boyd; Gerald Barry; Alain Kohl; Andres Merits; John K Fazakerley
Journal:  J Gen Virol       Date:  2007-12       Impact factor: 3.891

7.  Local type I IFN receptor signaling protects against virus spread within the central nervous system.

Authors:  Claudia N Detje; Thomas Meyer; Hauke Schmidt; Dorothea Kreuz; John K Rose; Ingo Bechmann; Marco Prinz; Ulrich Kalinke
Journal:  J Immunol       Date:  2009-02-15       Impact factor: 5.422

8.  Neuropeptide Y promotes TGF-beta1 production in RAW264.7 cells by activating PI3K pathway via Y1 receptor.

Authors:  Jiang-Rui Zhou; Zheng Xu; Chun-Lei Jiang
Journal:  Neurosci Bull       Date:  2008-06       Impact factor: 5.203

9.  Key role of T cell defects in age-related vulnerability to West Nile virus.

Authors:  James D Brien; Jennifer L Uhrlaub; Alec Hirsch; Clayton A Wiley; Janko Nikolich-Zugich
Journal:  J Exp Med       Date:  2009-11-09       Impact factor: 14.307

Review 10.  Latent viral infections of the nervous system: role of the host immune response.

Authors:  M Lafon
Journal:  Rev Neurol (Paris)       Date:  2009-12       Impact factor: 2.607

View more
  14 in total

1.  SARM1, Not MyD88, Mediates TLR7/TLR9-Induced Apoptosis in Neurons.

Authors:  Piyali Mukherjee; Clayton W Winkler; Katherine G Taylor; Tyson A Woods; Vinod Nair; Burhan A Khan; Karin E Peterson
Journal:  J Immunol       Date:  2015-09-30       Impact factor: 5.422

2.  BLT-humanized C57BL/6 Rag2-/-γc-/-CD47-/- mice are resistant to GVHD and develop B- and T-cell immunity to HIV infection.

Authors:  Kerry J Lavender; Wendy W Pang; Ronald J Messer; Amanda K Duley; Brent Race; Katie Phillips; Dana Scott; Karin E Peterson; Charles K Chan; Ulf Dittmer; Timothy Dudek; Todd M Allen; Irving L Weissman; Kim J Hasenkrug
Journal:  Blood       Date:  2013-09-10       Impact factor: 22.113

3.  Neuropeptide Y Negatively Influences Monocyte Recruitment to the Central Nervous System during Retrovirus Infection.

Authors:  Tyson A Woods; Min Du; Aaron Carmody; Karin E Peterson
Journal:  J Virol       Date:  2015-12-30       Impact factor: 5.103

4.  Defective eosinophil hematopoiesis ex vivo in inbred Rocky Mountain White (IRW) mice.

Authors:  Kimberly D Dyer; Katia E Garcia-Crespo; Caroline M Percopo; Aaron B Bowen; Tomonobu Ito; Karin E Peterson; Alasdair M Gilfillan; Helene F Rosenberg
Journal:  J Leukoc Biol       Date:  2011-08-30       Impact factor: 4.962

5.  Activation of the innate signaling molecule MAVS by bunyavirus infection upregulates the adaptor protein SARM1, leading to neuronal death.

Authors:  Piyali Mukherjee; Tyson A Woods; Roger A Moore; Karin E Peterson
Journal:  Immunity       Date:  2013-03-14       Impact factor: 31.745

6.  Toll-like receptor 7 suppresses virus replication in neurons but does not affect viral pathogenesis in a mouse model of Langat virus infection.

Authors:  David G Baker; Tyson A Woods; Niranjan B Butchi; Timothy M Morgan; R Travis Taylor; Piyanate Sunyakumthorn; Piyali Mukherjee; Kirk J Lubick; Sonja M Best; Karin E Peterson
Journal:  J Gen Virol       Date:  2012-11-07       Impact factor: 3.891

Review 7.  The homeostatic role of neuropeptide Y in immune function and its impact on mood and behaviour.

Authors:  A Farzi; F Reichmann; P Holzer
Journal:  Acta Physiol (Oxf)       Date:  2015-01-09       Impact factor: 6.311

8.  Genome-wide host responses against infectious laryngotracheitis virus vaccine infection in chicken embryo lung cells.

Authors:  Jeongyoon Lee; Walter G Bottje; Byung-Whi Kong
Journal:  BMC Genomics       Date:  2012-04-24       Impact factor: 3.969

9.  Plasma neuropeptide Y: a biomarker for symptom severity in chronic fatigue syndrome.

Authors:  Mary A Fletcher; Martin Rosenthal; Michael Antoni; Gail Ironson; Xiao R Zeng; Zachary Barnes; Jeanna M Harvey; Barry Hurwitz; Silvina Levis; Gordon Broderick; Nancy G Klimas
Journal:  Behav Brain Funct       Date:  2010-12-29       Impact factor: 3.759

Review 10.  Direct and indirect antimicrobial activities of neuropeptides and their therapeutic potential.

Authors:  Daria Augustyniak; Judyta Nowak; Fionnuala T Lundy
Journal:  Curr Protein Pept Sci       Date:  2012-12       Impact factor: 3.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.